Brief ReportInternational Journal of Contemporary Pediatrics

Publication:
Long-term use of a combination of atorvastatin and ezetimibe in children with homozygous familial hypercholesterolemia

Int J Contemp Pediatr. 2018;5(1):275-277.DOI10.18203/2349-3291.ijcp20175602

Read online (HTML) View on the journal's website(opens in a new tab)

Abstract

Background Homozygous familial hypercholesterolemia (HoFH) is an underdiagnosed and undertreated genetic disorder of lipoprotein metabolism associated with mortality during young age due to accelerated atherosclerosis. There is limited data on the efficacy of lipid lowering therapies in HoFH.

Methods Medical records of 3 children with HoFH who received a combination of atorvastatin and ezetimibe for a mean duration of 11.6±1.5 years were retrospectively analysed.

Results There was a significant decrease in total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) from the baseline levels (mean percent change in TC, LDL-C, TG and HDL-C of 58.5%, 56.2%, 67.5% and 29.7% respectively).

Conclusions We conclude that long-term use of a combination of atorvastatin and ezetimibe significantly lowers the plasma LDL-C concentrations in patients with HoFH without causing any significant adverse effects. Ours is the first study from India on long-term use of lipid modifying drug therapy in children with HoFH.

Keywords

Affiliations

  1. Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India
  2. Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Full item record